Earnings live updates: Eli Lilly stock pops as strong GLP-1 drug demand lifts results, ServiceNow stock plunges
Eli Lilly shares climbed following a strong earnings report driven by high demand for its blockbuster GLP-1 weight-loss medications, Zepbound and Mounjaro. The pharmaceutical company raised its full-year sales outlook as revenue surged 39 percent, fueled by obesity drug sales and international growth. Concurrently, ServiceNow stock experienced a sharp drop during the broader earnings updates. Eli Lilly also benefited from the Medicare Bridge boon while navigating deal charges that impacted its profit view, highlighting the strong financial momentum of the ongoing obesity-drug boom.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly stock jumped following strong Q3 earnings and raised sales guidance.
- ✓ Revenue surged 39 percent on blockbuster obesity drug demand and strong international growth.
- ✓ ServiceNow stock plunged during the earnings updates.
What changed
Eli Lilly reported explosive third-quarter earnings that beat estimates, leading the company to raise its sales outlook while ServiceNow shares plunged.
Live updates
-
Eli Lilly Stock Pops on GLP-1 Demand While ServiceNow Plunges
Eli Lilly shares climbed following a strong earnings report driven by high demand for its blockbuster GLP-1 weight-loss medications, Zepbound and Mounjaro. The pharmaceutical company raised its full-year sales outlook as revenue surged 39 percent, fueled by obesity drug sales and international growth. Concurrently, ServiceNow stock experienced a sharp drop during the broader earnings updates. Eli Lilly also benefited from the Medicare Bridge boon while navigating deal charges that impacted its profit view, highlighting the strong financial momentum of the ongoing obesity-drug boom.
Why it matters
Eli Lilly continues to ride a wave of high consumer demand for treatments targeting diabetes and weight loss, cementing its position as a major player in the biotech sector. Strong international performance and domestic sales have repeatedly forced leadership to lift annual guidance. Market watchers are closely monitoring how supply chains handle the sustained pressure of the obesity-drug boom.
What is confirmed
- Eli Lilly stock jumped following strong Q3 earnings and raised sales guidance.
- Revenue surged 39 percent on blockbuster obesity drug demand and strong international growth.
- ServiceNow stock plunged during the earnings updates.
What to watch next
- Monitor ongoing delivery volumes and manufacturing capacity for Zepbound and Mounjaro.
- Track further stock performance for Eli Lilly and ServiceNow as quarterly reporting continues.
confidence 90%Sources used for this update (22)
- github.com — GitHub - Feh/nocache: minimize caching effects
- classic.yarnpkg.com — nocache - Yarn
- directory.fsf.org — Nocache - Free Software Directory
- github.com — GitHub - helmetjs/nocache: Middleware to disable client-side...
- learn.microsoft.com — CacheControlHeaderValue.NoCache Property (System.Net.Http.Headers...
- www.smarty.net — {nocache} - Smarty
- www.godaddy.com — GoDaddy - View a non-cached version of my WordPress site
- www.marketbeat.com — Top Biotech Stocks To Research - October 14th | MarketBeat
- CNBC — Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
- WSJ — Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
- Reuters — Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
- Financial Times — Eli Lilly profits surge on demand for weight-loss drugs
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community